What did @elizajane1983 actually say?
Honestly? Almost nothing medically substantive. The transcript from this 63.9K-view video reads like garbled song lyrics, not a health testimonial. Phrases like "I'm counting shit but running out" and "No rest for God tops in my mind" don't map to any coherent claim about tirzepatide, GLP-1 therapy, or weight loss.
The actual spoken content appears to be background music or audio from another source, possibly a trending sound clip, playing over what the caption frames as a before-and-after transformation video. The hashtags do the heavy lifting here: #zepbound, #tirzepatide, #glp1journey, #weightlosstransformation. The visual framing implies a personal success story with Zepbound (tirzepatide), but the creator's voice, if it's even her voice, never explicitly claims anything about the drug's effects, dosing, or her health outcomes.
This is a format common on TikTok where trending audio gets layered over transformation visuals. The "claim" is made through implication and hashtag placement rather than direct statement.
Does the science back this up?
There's no specific claim to evaluate here, but the implicit message, that Zepbound produces dramatic physical transformation, is actually well-supported by clinical data. That part checks out, with important caveats.
The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found that tirzepatide at 15mg weekly produced a mean body weight reduction of 20.9% over 72 weeks in adults with obesity but without diabetes. That's a real, substantial effect size, larger than what was seen in semaglutide trials like STEP-1 (Wilding et al., 2021, NEJM), where participants lost a mean of 14.9% body weight. So the category of "significant transformation" the video implies is clinically plausible for some patients.
What the video doesn't say, and what matters: results vary considerably. Not everyone responds the same way. Side effect profiles, including nausea, vomiting, and gastrointestinal distress, affect adherence. And weight loss is typically sustained only while the medication continues.
What did they get wrong (or right)?
This is an unusual case. The creator didn't make explicit false claims because she didn't make coherent claims at all. The transcript is audio noise. So this isn't really a misinformation situation in the traditional sense. It's closer to passive promotion through visual implication.
What she got right, inadvertently: the hashtag #hypothyroidism in the caption is clinically relevant. Hypothyroidism is associated with weight gain and metabolic resistance, and GLP-1 receptor agonists are being studied in patients with thyroid-related metabolic dysfunction. That's an honest nod to a real comorbidity many people in the GLP-1 community share.
What she got wrong: the format itself. Transformation videos without context, without mentioning side effects, prescriber involvement, or lifestyle changes, create an incomplete picture. Viewers seeing a dramatic before-and-after tied to #zepbound may conclude the drug alone drives results. The clinical literature is clear that behavioral factors, dietary adherence, and patient selection all influence outcomes significantly.
Also worth noting: she hashtagged both #tirzepatide and #semaglutide. Those are different drugs with different mechanisms, trial data, and approval statuses. Conflating them, even implicitly, muddies the picture for people trying to understand their options.
What should you actually know?
If you found this video looking for information about Zepbound or GLP-1 therapy, here's what the research actually says, stripped of the aesthetic packaging.
Tirzepatide (Zepbound for weight management, Mounjaro for type 2 diabetes) is a dual GIP and GLP-1 receptor agonist. It's not the same drug as semaglutide (Wegovy, Ozempic), and the two have not been compared head-to-head in a large randomized trial as of 2024. The SURMOUNT program trials show strong efficacy data. But tirzepatide is a prescription medication that requires medical evaluation, and it's not appropriate for everyone.
People with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use tirzepatide. The FDA label carries a boxed warning on this point.
- Do not use transformation videos as a basis for treatment decisions.
- Ask a licensed prescriber whether GLP-1 therapy fits your specific health profile.
- Compounded versions of tirzepatide are not equivalent to FDA-approved Zepbound. Formulation, purity, and dosing accuracy differ.
- Weight regain after stopping is common. Aronne et al. (2024, NEJM) found significant weight return after tirzepatide discontinuation in the SURMOUNT-4 trial.